key: cord-0712021-thqvx6zd
authors: Yousaf, Ahmed; Gayam, Swapna; Feldman, Steve; Zinn, Zachary; Kolodney, Michael
title: Clinical Outcomes of CoVid-19 in Patients Taking Tumor Necrosis Factor Inhibitors and/or Methotrexate: A Multi-Center Research Network Study
date: 2020-09-11
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2020.09.009
sha: 1ed6da905c720fbb827954d42b24a27b7f6f98c9
doc_id: 712021
cord_uid: thqvx6zd

Background Data on the impact of biologics and immunomodulators on CoVid-19 related outcomes remains scarce. Objective To determine whether patients on tumor necrosis factor inhibitor (TNFi) and/or methotrexate are at increased risk of CoVid-19 related outcomes. Methods In this large comparative cohort study, a real-time search and analysis were performed on adult patients diagnosed with CoVid-19 and treated with TNFi and/or methotrexate versus those not treated. Likelihood of hospitalization and mortality were compared between groups with and without propensity score matching for confounding factors. Results 53,511,836 unique patient records were analyzed, of which 32,076 (0.06%) had a CoVid-19-related diagnosis documented starting after January 20, 2020. 214 patients with CoVid-19 were identified with recent TNFi or methotrexate exposure compared to 31,862 patients with CoVid-19 without TNFi or methotrexate exposure. After propensity matching, likelihood of hospitalization and mortality were not significantly different between the treatment and non-treatment group (risk ratio 0.91, 95% confidence interval [CI] 0.68-1.22, p=0.5260; risk ratio 0.87, 95% CI 0.42-1.78, p=0.6958, respectively). Limitations All TNFi may not behave similarly. Conclusion Our study suggests that patients with recent TNFi and/or methotrexate exposure do not have increased hospitalization or mortality compared to CoVid-19 patients without recent TNFi and/or methotrexate exposure.

Coronavirus disease 2019 (CoVid-19) is a global pandemic caused by the respiratory droplet transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). More than 2 million cases and 114,000 deaths have been reported in the United States alone. Given lack of effective vaccines or highly efficacious medical therapy, a global strategy of social distancing and quarantining has been implemented. High-risk patient characteristics include advanced age and various underlying comorbidities. The effect of immunosuppressive medications on CoVid-19 related outcomes remains largely unknown. 1 TNFi and MTX are used extensively in autoimmune inflammatory diseases including rheumatoid arthritis, psoriasis, psoriatic arthritis, inflammatory bowel disease, ankylosing spondylitis and others. Infliximab, adalimumab, etanercept, certolizumab, and golimumab are the five most commonly prescribed TNFi, and MTX is the most commonly prescribed DMARD in the United States. Tumor necrosis factor inhibitors (TNFi) increase the risk of certain infections such as upper respiratory infections, and cause flaring of pre-existing infectious diseases such as tuberculosis. 2 Likewise methotrexate (MTX), a disease-modifying anti-rheumatic drug (DMARD) used as monotherapy or in conjunction with biologic agents such as TNFi, can suppress immune function and increase infection risk. 3 Clinical Modification (ICD-10-CM) queries for comorbid diagnoses. As a federated network, TriNetX received a waiver from Western IRB since only aggregated counts and statistical summaries of de-identified information is distributed, no protected health information is received, and no study-specific activities are performed in retrospective analyses.

CoVid-19 patients age greater than or equal to 18 years old were queried on June 11, 2020 using ICD-10-CM diagnoses and terminology recommended by WHO and CDC (see Supplementary Appendix). Only patients diagnosed with a documented code after January 20, 2020 were included, following the first U.S. confirmed case. 4 Baseline characteristics were reported from documentation any time 6 months prior to CoVid-19 diagnosis. The index event was defined as contracting CoVid-19.

The observation period for outcome analysis was defined as date from index event to 45 days after index event. Primary outcomes studied were, from any cause, hospitalization and mortality. Outcomes analysis restricted the time window in order to capture primary outcomes related to CoVid-19. TriNetX provided specific inclusion criteria defining each outcome (see Supplementary Appendix).

A 1:1 propensity score match was performed for confounding variables previously found to be associated with CoVid-19. 5 Independent variables were chosen to assess for demographic disparities, including age at index event, gender, and race. Summary statistics were generated for all variables included in the propensity score match. A greedy nearest-neighbor matching algorithm was used with a caliper of 0.1 times the standard deviation. Chi-square analysis was conducted to determine significant differences between the TNFi and/or MTX cohort and the non-treatment cohort. Significance was set to an alpha level of 0.05 a priori. All statistical analyses were conducted on TriNetX. Patients in the MTX subgroup were older than the non-MTX group (58.7 ± 14.9 years vs. 53.2 ± 18.9 years, p = 0.0011). In both TNFi and MTX subgroups, the demographic trends of more female and white patients remained, as did having substantially more comorbidities. Therefore, a 1:1 propensity score match was J o u r n a l P r e -p r o o f 9 performed for all significant comorbidities, as well as age, gender, race, diabetes, and obesity.

Propensity score matching in the TNFi/MTX group yielded n=213 in both TNFi/MTX and non-TNFi/MTX groups. After matching, the groups were well- 6 Initial hypotheses maintained that cytokine inhibition may worsen CoVid-19 related outcomes via general immune suppression, however more recent hypotheses suggest inhibition of a cytokine storm may actually be beneficial. Anti-cytokine biologic therapies may prevent the CSS, which is the rationale for use of interleukin--6 inhibitors for treating CoVid-19. 7, alone showed no statistically significant difference in likelihood of hospitalization compared to patients not exposed to methotrexate (risk ratio 0.87, 95% CI 0.62-1.23, p=0.4272). There was insufficient data to calculate mortality for TNFi and methotrexate individually. In summary, our data showed similar likelihoods of hospitalization and mortality in the TNFi and/or methotrexate treatment group versus the non-treatment group. These results stood with and without propensity score matching for confounding factors. specialists who routinely prescribe these medications. 9 The large cohort is a strength of this study.

and/or methotrexate exposure within 12 months of CoVid-19 infection that may have captured some patients who were no longer taking the medication of concern at onset of CoVid-19 infection. Some patients in the data set were taking a TNFi and methotrexate and therefore may have been included twice in the subgroup analysis. 

Covid-19 in immune-mediated inflammatory diseases-case series from New York

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

Methotrexate, rheumatoid arthritis and infection risk-what is the evidence?

First case of 2019 novel coronavirus in the United States

Covid-19: risk factors for severe disease and death

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure (TOCIVID): Marius Henriksen

Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19: Regeneron Pharmaceuticals

Biologic drugs set to top 2012 sales